MCID: PNC129
MIFTS: 67

Pancreatic Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Adenocarcinoma

MalaCards integrated aliases for Pancreatic Adenocarcinoma:

Name: Pancreatic Adenocarcinoma 12 29 6 15 17
Adenocarcinoma of the Pancreas 12
Pancreas Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4074
NCIt 49 C8294
UMLS 71 C0281361

Summaries for Pancreatic Adenocarcinoma

Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreatic Adenocarcinoma, also known as adenocarcinoma of the pancreas, is related to pancreatic cancer and pancreatic ductal adenocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Desflurane and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, breast and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Pancreatic Adenocarcinoma

Diseases related to Pancreatic Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 676)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 35.5 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
2 pancreatic ductal adenocarcinoma 34.9 VEGFA TP53 STAT3 SMAD4 MUC4 KRAS
3 adenocarcinoma 34.6 VEGFA TP53 STAT3 SMAD4 PIK3CA MUC4
4 pancreatic acinar cell adenocarcinoma 33.5 SMAD4 KRAS HRAS
5 pancreatitis 32.8 TP53 SMAD4 MUC4 KRAS HRAS CDKN2A
6 colorectal cancer 32.7 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
7 breast cancer 32.7 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
8 cholangiocarcinoma 32.5 TP53 STAT3 SMAD4 PIK3CA MUC4 KRAS
9 hepatocellular carcinoma 32.4 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
10 pancreas disease 32.4 VEGFA TP53 SMAD4 KRAS HRAS EGFR
11 melanoma 32.3 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
12 bile duct cancer 32.3 VEGFA TP53 SMAD4 MUC4 KRAS HRAS
13 prostate cancer 32.3 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
14 neuroblastoma 32.3 VEGFA TP53 STAT3 SRC PIK3CA HRAS
15 intrahepatic cholangiocarcinoma 32.3 TP53 SMAD4 MUC4 KRAS ERBB2 EGFR
16 esophageal cancer 32.2 VEGFA TP53 STAT3 SMAD4 PIK3CA MUC4
17 exanthem 32.2 VEGFA KRAS HRAS ERBB2 EGFR AKT1
18 ovarian serous cystadenocarcinoma 32.2 VEGFA TP53 SMAD4 PIK3CA KRAS HRAS
19 endometrial cancer 32.2 VEGFA TP53 STAT3 SMAD4 PIK3CA KRAS
20 cervical cancer 32.2 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
21 glioblastoma multiforme 32.2 VEGFA TP53 STAT3 SRC PIK3CA KRAS
22 gastric adenocarcinoma 32.1 VEGFA TP53 STAT3 SMAD4 PIK3CA MUC4
23 adenoma 32.1 TP53 SMAD4 PIK3CA KRAS GNAS CTNNB1
24 colon adenocarcinoma 32.1 VEGFA TP53 SMAD4 PIK3CA KRAS ERBB2
25 pancreatic ductal carcinoma 32.1 VEGFA TP53 SMAD4 ERBB2 EGFR EGF
26 lung cancer susceptibility 3 32.1 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
27 squamous cell carcinoma 32.1 VEGFA TP53 STAT3 SMAD4 PIK3CA HRAS
28 ovarian cancer 32.1 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
29 gastric cancer 32.1 VEGFA TP53 STAT3 SMAD4 PIK3CA KRAS
30 in situ carcinoma 32.0 TP53 HRAS ERBB2 EGFR EGF CDKN2A
31 lymphoma 32.0 TP53 STAT3 PIK3CA EGFR CDKN2A CCND1
32 lynch syndrome 32.0 TP53 SRC SMAD4 PIK3CA KRAS HRAS
33 suppression of tumorigenicity 12 32.0 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
34 cystadenocarcinoma 32.0 VEGFA TP53 PIK3CA HRAS ERBB2 AKT1
35 leukemia, acute myeloid 32.0 VEGFA TP53 STAT3 SRC KRAS HRAS
36 mucinous adenocarcinoma 32.0 VEGFA TP53 KRAS ERBB2 EGFR CDKN2A
37 ovary adenocarcinoma 32.0 VEGFA TP53 SMAD4 PIK3CA KRAS HRAS
38 peutz-jeghers syndrome 31.9 TP53 SMAD4 GNAS EGFR CTNNB1 BRCA2
39 thyroid gland cancer 31.9 VEGFA TP53 SRC PIK3CA KRAS HRAS
40 renal cell carcinoma, nonpapillary 31.9 VEGFA TP53 STAT3 PIK3CA HRAS EGFR
41 gastrointestinal stromal tumor 31.9 VEGFA TP53 KRAS ERBB2 EGFR CDKN2A
42 gallbladder cancer 31.8 VEGFA TP53 STAT3 SMAD4 PIK3CA KRAS
43 myeloma, multiple 31.8 VEGFA TP53 STAT3 SRC KRAS HRAS
44 leukemia, chronic lymphocytic 31.7 VEGFA TP53 STAT3 SRC KRAS HRAS
45 papilloma 31.7 VEGFA TP53 KRAS EGFR CDKN2A CCND1
46 bladder urothelial carcinoma 31.7 VEGFA TP53 PIK3CA KRAS HRAS ERBB2
47 colorectal adenocarcinoma 31.7 VEGFA TP53 STAT3 KRAS HRAS ERBB2
48 diffuse large b-cell lymphoma 31.7 VEGFA TP53 STAT3 CDKN2A CCND1 AKT1
49 barrett esophagus 31.7 TP53 SMAD4 ERBB2 EGFR CTNNB1 CDKN2A
50 thyroid carcinoma 31.7 TP53 PIK3CA HRAS CTNNB1 AKT1

Graphical network of the top 20 diseases related to Pancreatic Adenocarcinoma:



Diseases related to Pancreatic Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Adenocarcinoma

UMLS symptoms related to Pancreatic Adenocarcinoma:


abdominal pain, pruritus, icterus

GenomeRNAi Phenotypes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.92 EGFR PIK3CA HRAS KRAS
2 Decreased viability GR00106-A-0 10.92 KRAS
3 Decreased viability GR00221-A-1 10.92 AKT1 CDKN2A EGFR PIK3CA HRAS KRAS
4 Decreased viability GR00221-A-2 10.92 AKT1 PIK3CA HRAS KRAS
5 Decreased viability GR00221-A-3 10.92 AKT1 CDKN2A ERBB2 HRAS
6 Decreased viability GR00221-A-4 10.92 AKT1 CDKN2A EGFR ERBB2 PIK3CA
7 Decreased viability GR00301-A 10.92 KRAS
8 Decreased viability GR00381-A-1 10.92 KRAS
9 Decreased viability GR00402-S-2 10.92 AKT1 CDKN2A EGFR ERBB2 PIK3CA HRAS
10 Decreased viability in esophageal squamous lineage GR00235-A 10.1 BRCA2 CCND1 CDKN2A CTNNB1 ERBB2 GNAS
11 Decreased cell migration GR00055-A-1 9.98 AKT1 CTNNB1 EGFR HRAS KRAS MAP2K2
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 CTNNB1 EGFR ERBB2 HRAS VEGFA
13 Decreased viability with paclitaxel GR00179-A-1 9.56 EGFR ERBB2 SRC
14 Decreased viability with paclitaxel GR00179-A-3 9.56 EGFR
15 Increased cell migration GR00055-A-3 9.55 CTNNB1 EGFR HRAS KRAS PIK3CA
16 Increased cell viability after pRB stimulation GR00230-A-1 9.26 AKT1 EGFR ERBB2 MAP2K2
17 Reduced mammosphere formation GR00396-S 9.17 CCND1 EGFR GNAS HRAS KRAS SMAD4

MGI Mouse Phenotypes related to Pancreatic Adenocarcinoma:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.55 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
2 growth/size/body region MP:0005378 10.54 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
3 behavior/neurological MP:0005386 10.53 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 ERBB2
4 cellular MP:0005384 10.52 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
5 cardiovascular system MP:0005385 10.5 AKT1 CCND1 CDKN2A CTNNB1 EGFR ERBB2
6 integument MP:0010771 10.5 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
7 homeostasis/metabolism MP:0005376 10.47 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
8 digestive/alimentary MP:0005381 10.45 BRCA2 CCND1 CDKN2A CTNNB1 EGF EGFR
9 mortality/aging MP:0010768 10.44 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
10 immune system MP:0005387 10.43 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
11 craniofacial MP:0005382 10.42 CCND1 CTNNB1 EGFR ERBB2 GNAS HRAS
12 embryo MP:0005380 10.41 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
13 neoplasm MP:0002006 10.41 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
14 hematopoietic system MP:0005397 10.39 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
15 nervous system MP:0003631 10.36 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
16 normal MP:0002873 10.28 AKT1 BRCA2 CCND1 CTNNB1 EGF EGFR
17 muscle MP:0005369 10.27 AKT1 CDKN2A CTNNB1 EGFR ERBB2 GNAS
18 limbs/digits/tail MP:0005371 10.24 BRCA2 CTNNB1 EGFR ERBB2 GNAS KRAS
19 liver/biliary system MP:0005370 10.22 AKT1 CDKN2A CTNNB1 EGFR GNAS KRAS
20 adipose tissue MP:0005375 10.18 AKT1 EGFR GNAS MAP2K2 PIK3CA STAT3
21 reproductive system MP:0005389 10.13 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
22 no phenotypic analysis MP:0003012 10.09 CDKN2A CTNNB1 EGFR GNAS HRAS KRAS
23 renal/urinary system MP:0005367 9.97 CTNNB1 EGFR GNAS HRAS KRAS SMAD4
24 respiratory system MP:0005388 9.97 AKT1 CCND1 CDKN2A CTNNB1 EGFR ERBB2
25 skeleton MP:0005390 9.89 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
26 pigmentation MP:0001186 9.85 CDKN2A CTNNB1 EGFR KRAS SRC TP53
27 vision/eye MP:0005391 9.4 CCND1 CDKN2A CTNNB1 EGF EGFR KRAS

Drugs & Therapeutics for Pancreatic Adenocarcinoma

Drugs for Pancreatic Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 348)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desflurane Approved Phase 4 57041-67-5 42113
2
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
3
Metronidazole Approved Phase 4 443-48-1 4173
4 Anesthetics, General Phase 4
5 Anesthetics, Inhalation Phase 4
6 Antitubercular Agents Phase 4
7
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
10
Curcumin Approved, Experimental, Investigational Phase 3 458-37-7 969516
11
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
12
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
13
Enoxaparin Approved Phase 2, Phase 3 9005-49-6 772
14
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
15
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
16
Ifosfamide Approved Phase 3 3778-73-2 3690
17
Ethanol Approved Phase 3 64-17-5 702
18
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
19
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
20
Dalteparin Approved Phase 3 9005-49-6
21
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
22
Clopidogrel Approved Phase 3 120202-66-6, 113665-84-2 60606
23
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
25
Rubitecan Investigational Phase 3 91421-42-0
26
Imidacloprid Vet_approved Phase 2, Phase 3 105827-78-9 86418
27
tipifarnib Investigational Phase 3 192185-72-1 159324
28
Irofulven Investigational Phase 3 158440-71-2
29 BB 1101 Phase 2, Phase 3
30 Cyclooxygenase Inhibitors Phase 3
31 Cyclooxygenase 2 Inhibitors Phase 3
32 Gastrins Phase 3
33 ON 01910 Phase 3
34 Antimitotic Agents Phase 3
35
Isophosphamide mustard Phase 3 0
36 Calcium, Dietary Phase 2, Phase 3
37 Central Nervous System Depressants Phase 3
38 Anti-Infective Agents, Local Phase 3
39 Antidotes Phase 3
40 Vitamin B Complex Phase 3
41 Hematinics Phase 3
42
asparaginase Phase 3
43 Vitamin B9 Phase 3
44 Folate Phase 3
45 Platelet Aggregation Inhibitors Phase 3
46 Fibrinolytic Agents Phase 3
47 Heparin, Low-Molecular-Weight Phase 3
48 Anticoagulants Phase 3
49 calcium heparin Phase 3
50 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid Phase 3

Interventional clinical trials:

(show top 50) (show all 808)
# Name Status NCT ID Phase Drugs
1 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
2 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
3 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
4 Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
5 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
6 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
7 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Not yet recruiting NCT03891979 Phase 4 Antibiotics and Pembrolizumab
8 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
9 Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing. Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
11 Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX] Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
12 Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients Unknown status NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
13 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
14 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
15 A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen Unknown status NCT00088660 Phase 3
16 Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas. Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
17 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
18 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3 Gemcitabine;Curcumin;Celebrex
19 Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas Unknown status NCT02514928 Phase 3
20 Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
21 A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection Unknown status NCT02506842 Phase 3 nab-paclitaxel;gemcitabine;oxaliplatin;folinic acid;fluorouracil
22 CROSSFIRE Trial: Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival After Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation Unknown status NCT02791503 Phase 2, Phase 3
23 A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
24 Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma Completed NCT00033735 Phase 3 fluorouracil;Irofulven
25 European Study Group For Pancreatic Cancer - Trial 3 Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
26 A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
27 Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
28 A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
29 A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02436668 Phase 3 Ibrutinib;Gemcitabine;Nab-paclitaxel
30 Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4) Completed NCT00044031 Phase 3
31 A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
32 Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
33 Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone Completed NCT00416507 Phase 3 fluorouracil;gemcitabine hydrochloride;liposomal cisplatin
34 A Randomized, Controlled Trial of Intraoperative Celiac Plexus Neurolysis for Patients With Operable (Resectable and Unresectable) Pancreatic and Periampullary Cancer Completed NCT00806611 Phase 3
35 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Completed NCT00099294 Phase 3 Glufosfamide
36 Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
37 Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial. Completed NCT00003029 Phase 3 cisplatin;fluorouracil
38 A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
39 A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Completed NCT00058149 Phase 3 gemcitabine hydrochloride;oxaliplatin
40 A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer Completed NCT00032175 Phase 3 capecitabine;gemcitabine hydrochloride
41 An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
42 A Phase III, Double-Blind, Placebo Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus R115777 in Patients With Advanced Pancreatic Cancer Completed NCT00005648 Phase 3 Gemcitabine with R115777;Gemcitabine with Placebo
43 Randomized Controlled Study: Comparison Between Extended and Standard Pancreatoduodenectomy Completed NCT00679913 Phase 3
44 A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC] Completed NCT00425360 Phase 3 capecitabine;gemcitabine hydrochloride
45 Randomized Phase II/III Study Comparing Gemcitabine Followed by Gemcitabine Plus Concomitant Radiation (50.4 Gy) Versus Control After Curative Pancreaticoduodenectomy for Pancreatic Head Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
46 A Randomized Phase III Study Of Gemcitabine In Combination With Radiation Therapy Versus Gemcitabine Alone In Patients With Localized, Unresectable Pancreatic Cancer Completed NCT00057876 Phase 3 Gemcitabine
47 A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer Completed NCT00026338 Phase 3 erlotinib hydrochloride;gemcitabine hydrochloride
48 A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
49 Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression Completed NCT00303758 Phase 3 cisplatin;fluorouracil;gemcitabine hydrochloride;leucovorin calcium
50 A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT) Completed NCT00785421 Phase 2, Phase 3 enoxaparin;chemotherapy with LMWH - enoxaparin;only chemotherapy

Search NIH Clinical Center for Pancreatic Adenocarcinoma

Genetic Tests for Pancreatic Adenocarcinoma

Genetic tests related to Pancreatic Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 29

Anatomical Context for Pancreatic Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Adenocarcinoma:

40
Pancreas, Breast, Liver, Lung, T Cells, Lymph Node, Endothelial

Publications for Pancreatic Adenocarcinoma

Articles related to Pancreatic Adenocarcinoma:

(show top 50) (show all 6868)
# Title Authors PMID Year
1
MSH6 gene pathogenic variant identified in familial pancreatic cancer in the absence of colon cancer. 61
31851094 2020
2
ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. 61
31823171 2020
3
National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection. 61
31691112 2020
4
Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. 61
31825664 2020
5
Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. 61
32034575 2020
6
Transcatheter arterial embolization for gastrointestinal bleeding related to pancreatic adenocarcinoma: clinical efficacy and predictors of clinical outcome. 61
31877509 2020
7
Metabolome of pancreatic juice delineates distinct clinical profiles of pancreatic cancer and reveals a link between glucose metabolism and PD-1+ cells. 61
32019781 2020
8
Synthetic lethality in pancreatic cancer: discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with olaparib. 61
32037829 2020
9
Relevance of positive resection margins in ductal pancreatic adenocarcinoma and prognostic factors. 61
31395275 2020
10
CLytA-DAAO, Free and Immobilized in Magnetic Nanoparticles, induces Cell Death in Human Cancer Cells. 61
32028649 2020
11
Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. 61
31605347 2020
12
Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. 61
31863835 2020
13
Dynamics of Cell Death After Conventional IRE and H-FIRE Treatments. 61
32026232 2020
14
Impact of structured report on the quality of preoperative CT staging of pancreatic ductal adenocarcinoma: assessment of intra- and inter-reader variability. 61
31686180 2020
15
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. 61
31789476 2020
16
Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think? 61
32018143 2020
17
Prognostic impact of simultaneous venous resections during surgery for resectable pancreatic cancer. 61
31980308 2020
18
From tumor microenvironment communicants to biomarker discovery: Selectively packaged extracellular vesicular cargoes in pancreatic cancer. 61
32005635 2020
19
Oral microbial community composition is associated with pancreatic cancer: A case-control study in Iran. 61
31750624 2020
20
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. 61
30852003 2020
21
Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. 61
31812026 2020
22
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. 61
31932696 2020
23
Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. 61
31917116 2020
24
CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. 61
31915999 2020
25
S-1-Associated Hypertriglyceridemia in a Patient With Pancreatic Adenocarcinoma. 61
31618087 2020
26
HOXC11 functions as a novel oncogene in human colon adenocarcinoma and kidney renal clear cell carcinoma. 61
31923422 2020
27
Quantifying Reoxygenation in Pancreatic Cancer During Stereotactic Body Radiotherapy. 61
32005829 2020
28
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. 61
31291709 2020
29
Factors Related to Development of Pancreatic Adenocarcinoma in Patients With Chronic Pancreatitis on Long-term Follow-up: A Database Study. 61
31852038 2020
30
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. 61
31694832 2020
31
First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. 61
31958291 2020
32
A commentary on "Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis" [Int. J. Surg. 2019, 72:59-68]. 61
31759117 2020
33
Follicular pancreatitis: A rare pancreatic inflammatory pseudotumor. 61
31756593 2020
34
Outcomes of duodenal stenting: Experience in a French tertiary center with 220 cases. 61
31401023 2020
35
Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and without diabetes. 61
31791885 2020
36
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial. 61
31856081 2020
37
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. 61
31760314 2020
38
Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. 61
31669204 2020
39
Prognostic impact of tumour-infiltrating lymphocytes and cancer-associated fibroblasts in patients with pancreatic adenocarcinoma of the body and tail undergoing resection. 61
31960955 2020
40
Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. 61
32024004 2020
41
Testicular Metastasis of Pancreatic Carcinoma on FDG-PET/CT. 61
31693625 2020
42
Cellular Pharmacodynamics of a Novel Pyrrolo[3,2-d]pyrimidine Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism. 61
31707355 2020
43
Treatment patterns and outcomes for pancreatic tumors in children: an analysis of the National Cancer Database. 61
31989243 2020
44
OSpaad: An online tool to perform survival analysis by integrating gene expression profiling and long-term follow-up data of 1319 pancreatic carcinoma patients. 61
31912599 2020
45
An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma. 61
31936786 2020
46
Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencing. 61
31958074 2020
47
Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors. 61
31975647 2020
48
Implications of Prolonged Time to Pancreaticoduodenectomy After Neoadjuvant Chemoradiation. 61
31401247 2020
49
Sequential molecular and cytologic analyses provides a complementary approach to the diagnosis of pancreatic cystic lesions: a decade of clinical practice. 61
31711852 2020
50
New addiction to the NRF2-related factor NRF3 in cancer cells: Ubiquitin-independent proteolysis through the 20S proteasome. 61
31742837 2020

Variations for Pancreatic Adenocarcinoma

ClinVar genetic disease variations for Pancreatic Adenocarcinoma:

6 (show top 50) (show all 353) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_000546.5(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
4 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
5 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
6 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
7 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
8 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
9 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
10 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
11 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr)SNV Pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
12 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met)SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
13 MAP2K2 NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)SNV Pathogenic 8273 rs121434498 19:4117551-4117551 19:4117553-4117553
14 SMAD4 NM_005359.5(SMAD4):c.1081C>T (p.Arg361Cys)SNV Pathogenic 8543 rs80338963 18:48591918-48591918 18:51065548-51065548
15 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
16 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
17 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
18 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
19 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
20 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
21 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
22 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
23 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
24 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
25 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
26 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
27 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
28 SMAD4 NM_005359.5(SMAD4):c.1082G>A (p.Arg361His)SNV Pathogenic 24832 rs377767347 18:48591919-48591919 18:51065549-51065549
29 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
30 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
31 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
32 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
33 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
34 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
35 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
36 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
37 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu)SNV Pathogenic 232497 rs876659802 17:7577105-7577105 17:7673787-7673787
38 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
39 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro)SNV Pathogenic/Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
40 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
41 ERBB2 NM_004448.3(ERBB2):c.2524G>A (p.Val842Ile)SNV Pathogenic/Likely pathogenic 375994 rs1057519738 17:37881332-37881332 17:39725079-39725079
42 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro)SNV Pathogenic/Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
43 TP53 NM_000546.5(TP53):c.701A>G (p.Tyr234Cys)SNV Pathogenic/Likely pathogenic 127820 rs587780073 17:7577580-7577580 17:7674262-7674262
44 TP53 NM_000546.5(TP53):c.535C>T (p.His179Tyr)SNV Pathogenic/Likely pathogenic 127815 rs587780070 17:7578395-7578395 17:7675077-7675077
45 KRAS NM_033360.4(KRAS):c.183A>T (p.Gln61His)SNV Pathogenic/Likely pathogenic 45117 rs17851045 12:25380275-25380275 12:25227341-25227341
46 HRAS NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)SNV Pathogenic/Likely pathogenic 35554 rs104894228 11:534286-534286 11:534286-534286
47 CTNNB1 NM_001904.4(CTNNB1):c.98C>T (p.Ser33Phe)SNV Pathogenic/Likely pathogenic 17583 rs121913400 3:41266101-41266101 3:41224610-41224610
48 CTNNB1 NM_001904.4(CTNNB1):c.122C>T (p.Thr41Ile)SNV Pathogenic/Likely pathogenic 17587 rs121913413 3:41266125-41266125 3:41224634-41224634
49 GNAS NM_001077488.4(GNAS):c.604C>T (p.Arg202Cys)SNV Pathogenic/Likely pathogenic 15933 rs11554273 20:57484420-57484420 20:58909365-58909365
50 GNAS NM_001077488.4(GNAS):c.605G>A (p.Arg202His)SNV Pathogenic/Likely pathogenic 15934 rs121913495 20:57484421-57484421 20:58909366-58909366

Expression for Pancreatic Adenocarcinoma

Search GEO for disease gene expression data for Pancreatic Adenocarcinoma.

Pathways for Pancreatic Adenocarcinoma

Pathways related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.4 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
2
Show member pathways
14.26 VEGFA TP53 STAT3 SRC PIK3CA MUC4
3
Show member pathways
14.05 VEGFA TP53 STAT3 SRC SMAD4 MAP2K2
4
Show member pathways
14.02 TP53 SRC MAP2K2 KRAS HRAS GNAS
5
Show member pathways
13.96 STAT3 SRC SMAD4 PIK3CA MUC4 MAP2K2
6
Show member pathways
13.92 VEGFA TP53 STAT3 SRC SMAD4 MAP2K2
7
Show member pathways
13.91 TP53 STAT3 SRC SMAD4 MAP2K2 KRAS
8
Show member pathways
13.81 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
9
Show member pathways
13.8 SRC SMAD4 MAP2K2 KRAS HRAS GNAS
10
Show member pathways
13.77 VEGFA STAT3 SRC SMAD4 PIK3CA MAP2K2
11
Show member pathways
13.67 TP53 SRC PIK3CA KRAS HRAS ERBB2
12
Show member pathways
13.67 TP53 STAT3 SRC KRAS HRAS GNAS
13
Show member pathways
13.67 VEGFA STAT3 SRC PIK3CA MAP2K2 KRAS
14
Show member pathways
13.63 VEGFA TP53 STAT3 SRC PIK3CA MAP2K2
15
Show member pathways
13.58 VEGFA TP53 SRC PIK3CA KRAS HRAS
16
Show member pathways
13.56 SRC MAP2K2 KRAS HRAS GNAS ERBB2
17
Show member pathways
13.55 VEGFA SRC MAP2K2 KRAS HRAS GNAS
18
Show member pathways
13.54 SRC SMAD4 KRAS HRAS ERBB2 EGFR
19
Show member pathways
13.5 TP53 STAT3 SRC MAP2K2 KRAS HRAS
20
Show member pathways
13.36 TP53 STAT3 SRC SMAD4 PIK3CA MAP2K2
21
Show member pathways
13.34 TP53 SRC MAP2K2 KRAS HRAS GNAS
22
Show member pathways
13.33 VEGFA SRC MAP2K2 KRAS HRAS GNAS
23
Show member pathways
13.32 TP53 SRC PIK3CA ERBB2 EGFR EGF
24
Show member pathways
13.3 STAT3 MAP2K2 KRAS HRAS GNAS EGFR
25
Show member pathways
13.29 SRC SMAD4 KRAS HRAS GNAS EGFR
26
Show member pathways
13.29 VEGFA TP53 STAT3 SRC MAP2K2 KRAS
27
Show member pathways
13.25 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
28
Show member pathways
13.24 VEGFA TP53 SRC PIK3CA MAP2K2 KRAS
29
Show member pathways
13.2 VEGFA STAT3 SRC PIK3CA MAP2K2 KRAS
30
Show member pathways
13.19 TP53 STAT3 SRC MAP2K2 KRAS HRAS
31
Show member pathways
13.18 STAT3 SRC PIK3CA MAP2K2 KRAS HRAS
32
Show member pathways
13.17 MAP2K2 KRAS HRAS GNAS EGFR CTNNB1
33
Show member pathways
13.16 STAT3 SRC PIK3CA KRAS HRAS GNAS
34
Show member pathways
13.11 SRC MAP2K2 KRAS HRAS CTNNB1 AKT1
35
Show member pathways
13.11 SRC PIK3CA MAP2K2 KRAS HRAS EGFR
36 13.07 VEGFA TP53 MAP2K2 KRAS HRAS ERBB2
37
Show member pathways
13.06 TP53 PIK3CA MAP2K2 KRAS HRAS CDKN2A
38
Show member pathways
13.06 SRC MAP2K2 KRAS HRAS GNAS CTNNB1
39
Show member pathways
13.04 STAT3 SRC PIK3CA MAP2K2 KRAS HRAS
40
Show member pathways
13.04 TP53 SRC PIK3CA KRAS HRAS ERBB2
41
Show member pathways
13.03 STAT3 PIK3CA MAP2K2 KRAS HRAS CCND1
42
Show member pathways
13.03 TP53 STAT3 SRC PIK3CA MAP2K2 KRAS
43
Show member pathways
13.02 TP53 STAT3 PIK3CA MAP2K2 CCND1 AKT1
44
Show member pathways
13.02 VEGFA SRC PIK3CA MAP2K2 KRAS HRAS
45
Show member pathways
13.01 VEGFA STAT3 SRC PIK3CA MAP2K2 KRAS
46
Show member pathways
12.98 STAT3 SRC MAP2K2 KRAS HRAS GNAS
47
Show member pathways
12.98 VEGFA STAT3 SRC PIK3CA MAP2K2 KRAS
48
Show member pathways
12.97 STAT3 SRC SMAD4 KRAS HRAS EGFR
49
Show member pathways
12.96 TP53 STAT3 MAP2K2 KRAS HRAS EGFR
50
Show member pathways
12.96 VEGFA TP53 STAT3 SRC PIK3CA MAP2K2

GO Terms for Pancreatic Adenocarcinoma

Cellular components related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.16 VEGFA TP53 SRC PIK3CA MUC4 MAP2K2
2 plasma membrane GO:0005886 10.13 STAT3 SRC PIK3CA MUC4 KRAS HRAS
3 cytosol GO:0005829 9.83 TP53 STAT3 SRC SMAD4 PIK3CA MAP2K2
4 perinuclear region of cytoplasm GO:0048471 9.7 SRC MAP2K2 HRAS GNAS ERBB2 EGFR
5 transcription factor complex GO:0005667 9.67 TP53 STAT3 SMAD4 CTNNB1
6 cytoplasm GO:0005737 9.55 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA

Biological processes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.34 VEGFA STAT3 SRC KRAS HRAS GNAS
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.26 VEGFA TP53 STAT3 SMAD4 HRAS EGFR
3 cell differentiation GO:0030154 10.24 VEGFA TP53 SRC SMAD4 EGFR CTNNB1
4 regulation of transcription by RNA polymerase II GO:0006357 10.23 VEGFA TP53 STAT3 SMAD4 ERBB2 EGFR
5 negative regulation of transcription by RNA polymerase II GO:0000122 10.22 VEGFA TP53 STAT3 SMAD4 CTNNB1 CCND1
6 protein phosphorylation GO:0006468 10.19 SRC PIK3CA MAP2K2 ERBB2 EGFR CCND1
7 negative regulation of apoptotic process GO:0043066 10.17 VEGFA TP53 STAT3 SRC EGFR CTNNB1
8 phosphorylation GO:0016310 10.17 STAT3 SRC PIK3CA MAP2K2 ERBB2 EGFR
9 negative regulation of cell proliferation GO:0008285 10.15 TP53 STAT3 SMAD4 HRAS CTNNB1 CDKN2A
10 intracellular signal transduction GO:0035556 10.13 SRC SMAD4 ERBB2 EGFR AKT1
11 positive regulation of apoptotic process GO:0043065 10.11 TP53 SRC CTNNB1 CDKN2A AKT1
12 response to drug GO:0042493 10.09 TP53 STAT3 SRC GNAS CTNNB1 CCND1
13 negative regulation of gene expression GO:0010629 10.06 VEGFA TP53 MAP2K2 HRAS CTNNB1 AKT1
14 MAPK cascade GO:0000165 10.05 MAP2K2 KRAS HRAS ERBB2 EGFR EGF
15 in utero embryonic development GO:0001701 10.04 VEGFA TP53 SMAD4 CTNNB1
16 positive regulation of protein kinase B signaling GO:0051897 10.03 SRC PIK3CA ERBB2 EGFR EGF
17 positive regulation of cell migration GO:0030335 10.03 VEGFA STAT3 HRAS EGFR EGF CEACAM6
18 cytokine-mediated signaling pathway GO:0019221 10.02 VEGFA TP53 STAT3 PIK3CA KRAS CCND1
19 protein autophosphorylation GO:0046777 10.01 SRC ERBB2 EGFR AKT1
20 positive regulation of transcription, DNA-templated GO:0045893 10 TP53 STAT3 SRC SMAD4 MAP2K2 EGFR
21 cellular response to hypoxia GO:0071456 9.99 VEGFA TP53 SRC AKT1
22 peptidyl-tyrosine phosphorylation GO:0018108 9.99 SRC MAP2K2 ERBB2 EGFR EGF
23 regulation of cell proliferation GO:0042127 9.99 TP53 STAT3 SRC SMAD4 EGFR CTNNB1
24 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.98 SRC MUC4 KRAS HRAS
25 response to estradiol GO:0032355 9.97 STAT3 EGFR CTNNB1 CCND1
26 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.97 VEGFA TP53 SRC EGF
27 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.96 VEGFA PIK3CA EGFR AKT1
28 liver development GO:0001889 9.96 PIK3CA KRAS EGFR CCND1
29 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA KRAS HRAS ERBB2 EGFR CCND1
30 Ras protein signal transduction GO:0007265 9.94 TP53 KRAS HRAS CDKN2A
31 cellular response to growth factor stimulus GO:0071363 9.93 ERBB2 EGFR CTNNB1 AKT1
32 cell proliferation GO:0008283 9.92 TP53 STAT3 SRC SMAD4 EGFR CTNNB1
33 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.91 VEGFA SRC AKT1
34 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.9 VEGFA SRC PIK3CA
35 negative regulation of neuron death GO:1901215 9.9 STAT3 CTNNB1 AKT1
36 positive regulation of cell proliferation GO:0008284 9.9 VEGFA STAT3 KRAS HRAS ERBB2 EGFR
37 T cell costimulation GO:0031295 9.89 SRC PIK3CA AKT1
38 positive regulation of cell adhesion GO:0045785 9.89 VEGFA SRC ERBB2
39 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.88 EGFR CCND1 AKT1
40 cellular response to epidermal growth factor stimulus GO:0071364 9.87 ERBB2 EGFR AKT1
41 negative regulation of Notch signaling pathway GO:0045746 9.87 EGFR EGF AKT1
42 phosphatidylinositol 3-kinase signaling GO:0014065 9.86 PIK3CA ERBB2 AKT1
43 regulation of cell motility GO:2000145 9.86 ERBB2 EGFR EGF
44 cell aging GO:0007569 9.85 TP53 HRAS BRCA2
45 cellular response to reactive oxygen species GO:0034614 9.85 TP53 SRC EGFR AKT1
46 positive regulation of epithelial cell proliferation GO:0050679 9.85 VEGFA HRAS ERBB2 EGFR CCND1
47 response to X-ray GO:0010165 9.84 TP53 CCND1 BRCA2
48 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.83 SRC EGFR CCND1 AKT1
49 epidermal growth factor receptor signaling pathway GO:0007173 9.83 SRC PIK3CA EGFR EGF AKT1
50 negative regulation of anoikis GO:2000811 9.82 SRC PIK3CA CEACAM6

Molecular functions related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.38 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
2 identical protein binding GO:0042802 9.97 VEGFA TP53 STAT3 SMAD4 ERBB2 EGFR
3 protein kinase activity GO:0004672 9.93 SRC MAP2K2 ERBB2 EGFR CCND1 AKT1
4 nucleotide binding GO:0000166 9.91 MAP2K2 KRAS HRAS ERBB2 EGFR
5 transcription factor binding GO:0008134 9.89 TP53 STAT3 CTNNB1 CDKN2A CCND1
6 kinase activity GO:0016301 9.86 SRC PIK3CA MAP2K2 ERBB2 EGFR CDKN2A
7 enzyme binding GO:0019899 9.85 TP53 SRC EGFR CTNNB1 CCND1 AKT1
8 protein tyrosine kinase activity GO:0004713 9.73 SRC MAP2K2 ERBB2 EGFR
9 RNA polymerase II transcription factor binding GO:0001085 9.71 TP53 SMAD4 CTNNB1
10 disordered domain specific binding GO:0097718 9.65 TP53 CTNNB1 CDKN2A
11 protein phosphatase binding GO:0019903 9.55 TP53 STAT3 ERBB2 EGFR CTNNB1
12 nitric-oxide synthase regulator activity GO:0030235 9.52 EGFR AKT1
13 protein C-terminus binding GO:0008022 9.43 TP53 SRC HRAS ERBB2 CTNNB1 BRCA2
14 protein kinase binding GO:0019901 9.23 TP53 STAT3 SRC EGFR CTNNB1 CDKN2A

Sources for Pancreatic Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....